New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2014
12:50 EDTARNAArena rallies after partner announces broader coverage for Belviq
Arena Pharmaceuticals (ARNA) partner Eisai announced earlier that it has secured improved patient access of weight loss drug Belviq with CVS Caremark (CVS) and Aetna (AET). CVS Caremark customers have broadened the coverage of Eisai's Belviq, according to Fingertip Formulary, a database of formulary information, the company said. Fingertip Formulary reports that depending on the design of the health plan or employer benefit, eligible CVS Caremark members may have access to Belviq in either a preferred or non-preferred brand position, it added. In addition, Fingertip Formulary states that the number of insured commercial lives in the United States with coverage for Belviq now exceeds 50%. Eisai added that Aetna recently announced that it would offer Belviq as a preferred brand to eligible patients as part of its pilot program to self-insured plan sponsors. Belviq is a registered trademark of Arena Pharmaceuticals (ARNA). Shares of Arena are up 5% to $6.28 in early afternoon trading.
News For ARNA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
10:02 EDTARNAArena reports lorcaserin combo doubles weight loss in study
Subscribe for More Information
09:50 EDTARNAArena Pharmaceuticals shares should go higher today, says Piper Jaffray
Subscribe for More Information
09:47 EDTARNAArena Pharmaceuticals says BELVIQ U.S. quarterly sales $16.8M
Arena Pharmaceuticals disclosed that Eisai reported net sales of BELVIQ in the United States for the quarter ended September 30 of approximately $16.8M. Eisai markets and distributes BELVIQ in the United States under a marketing and supply agreement with Arena.
October 29, 2014
08:18 EDTARNAArena press release lacking key data, TheStreet's Feuerstein says
Subscribe for More Information
October 28, 2014
18:25 EDTARNAArena Pharmaceuticals, Eisai study meets primary safety objective
Eisai and Arena Pharmaceuticals announced top-line results of a pilot study to assess the safety of lorcaserin HCl, a serotonin 2C receptor agonist, when coadministered with phentermine HCl. The results of the investigational study demonstrate that the short-term combination of lorcaserin plus phentermine does not appear to be associated with an exacerbation in the proportion of pre-specified adverse events compared to therapy with lorcaserin alone. The coadministration of lorcaserin and phentermine for weight management is investigational. The efficacy and safety of coadministration of lorcaserin and other weight loss products such as phentermine have not been established.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use